CLEC7A and neoplasm: Taken together, both ibrutinib and acalabrutinib can inhibit TLR-BTK, TREM-1-BTK and Dectin-1-BTK signaling pathways in monocytes and macrophages, resulting in reduced production of inflammatory cytokines and chemokines as well as impaired phagocytosis of tumor cells and infectious pathogens (Table 2 and Figure 1).